Anzeige
Meldung des Tages: Revolutionäre Entwicklung im Megatrend – Der KI-Durchbruch für Pflege und Sicherheit!

Hoth Therapeutics Aktie News

Aktie
WKN:  A3DZJ0 ISIN:  US44148G2049 US-Symbol:  HOTH Branche:  Biotechnologie Land:  USA
0,8023 $
-0,0363 $
-4,33%
0,6799 € 04.02.26
Depot/Watchlist
Marktkapitalisierung *
11,28 Mio. €
Streubesitz
87,82%
KGV
-1,23
Index-Zuordnung
-

Hoth Therapeutics News

22.01.26 - PR Newswire
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-​Label PK Cohort of EGFR-​Treated Cancer Patients PR Newswire
21.01.26 - PR Newswire
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PR Newswire
15.01.26 - PR Newswire
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-​Country Site Activation PR Newswire
02.01.26 - PR Newswire
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PR Newswire
03.12.25 - PR Newswire
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-​Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic ...
01.12.25 - PR Newswire
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 PR Newswire
20.11.25 - PR Newswire
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities PR Newswire
27.10.25 - PR Newswire
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease PR Newswire
21.10.25 - PR Newswire
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-​KIT-Driven Cancers PR Newswire
08.10.25 - PR Newswire
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform PR Newswire
07.10.25 - PR Newswire
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
Hoth Therapeutics CEO Robb Knie to Present at BIO-​Europe in Vienna, Austria November 3-5, 2025 PR Newswire
24.09.25 - PR Newswire
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-​Induced Hypersensitivity, Radiotherapy-​Induced Rash, and MENIN Inhibitor-​Associated Skin ...
16.09.25 - PR Newswire
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History PR ...
10.09.25 - PR Newswire
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-​Induced Skin Toxicities ...
04.09.25 - PR Newswire
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development PR Newswire
02.09.25 - PR Newswire
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-​Tumor Activity and GLP-​Validated Bioanalytical Results, Exceeding Regulatory ...
29.07.25 - PR Newswire
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe PR Newswire
22.07.25 - PR Newswire
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-​by-Side Study vs. Semaglutide Begins PR Newswire
25.06.25 - PR Newswire
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-​in-class GDNF-​based therapy licensed from ...
23.06.25 - PR Newswire
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »